GF CSI Innovative Drugs Industry ETF(515120) Falls 1.23%, with Latest Net Capital Outflow of RMB 89.0930 Million

NewTimeSpace (newtimespace.com) News, – As of 10:09 on August 6, 2026, GF Innovative Drug ETF (515120) fell 1.23%, with its latest price at RMB 0.64. Over a longer horizon, as of August 5, 2026, the ETF had accumulated a gain of 1.89% over the past week.

In terms of liquidity, GF Innovative Drug ETF recorded a turnover rate of 3.06% during the session, with trading volume reaching RMB 368 million. Over a longer period, as of August 5, the ETF’s average daily turnover over the past month was RMB 994 million, ranking among the top 2 comparable funds.

In terms of scale, the ETF’s scale grew by RMB 22.7088 million over the past week, achieving significant growth and ranking 3rd among 7 comparable funds in new scale additions. (Data source: Wind)

In terms of units, the ETF’s share count grew by 388 million units over the past month, achieving significant growth and ranking 2nd among 7 comparable funds in new share additions. (Data source: Wind)

On capital flows, the latest net capital outflow for GF Innovative Drug ETF was RMB 89.0930 million. Over a longer horizon, the ETF saw net inflows on 13 out of the past 23 trading days, with total net inflow of RMB 265 million, averaging RMB 11.5341 million per day. (Data source: Wind)

Data shows that leveraged funds are continuing to position themselves. The latest margin buying amount for GF Innovative Drug ETF reached RMB 57.0711 million, with its latest margin balance standing at RMB 383 million. (Data source: Wind)

As of August 5, the net value of GF Innovative Drug ETF had risen 36.48% over the past 2 years. In terms of return capability, as of August 5, 2026, since its inception, the ETF achieved a highest single‑month return of 23.00%, a longest consecutive winning streak of 5 months with a cumulative gain of 32.68%, and an average monthly return of 5.46% during up months. As of August 5, 2026, the ETF’s 3‑month excess annualized return over its benchmark was 4.24%.

In terms of drawdown, as of August 5, 2026, the ETF’s half‑year drawdown relative to its benchmark was 0.14%, indicating relatively low drawdown risk among comparable funds. The recovery period after drawdown was 36 days.

On fees, GF Innovative Drug ETF charges a management fee of 0.50% and a custody fee of 0.10%.

On tracking accuracy, as of August 5, 2026, the ETF’s 5‑year tracking error was 0.026%, the highest tracking precision among comparable funds.

GF Innovative Drug ETF closely tracks the CSI Innovative Drug Industry Index. The index selects no more than 50 representative listed company securities whose primary business involves innovative drug research and development as index samples, reflecting the overall performance of listed companies in the innovative drug industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.